Sign in
CompletedPhase 2

A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults

Key facts

Who runs it
Pfizer
Where
Atlantis, Charlottesville, Columbus, Hialeah, Honolulu, Houston, Lake Forest, Las Vegas, Melbourne, Mesquite, Milford, Nashville, North Las Vegas, Orlando, Peoria, Portsmouth, Rochester, San Antonio, Springfield, Stockbridge, Tomball, Tustin, Walnut Creek, Washington D.C., and Winter Park, United StatesSee the 30 sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
644 people enrolled
Started
31 Jan 2024
Ended
13 Sept 2024
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • BNT162b2 (Omi XBB.1.5)/RIV
  • BNT162b2 (Omi XBB.1.5)
  • RIV
  • Normal saline placebo
Record updated
30 September 2025

Who can take part

Age
50 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Male or female participants aged 50 years or older at Visit 1 (Day 1)
  • Participants who are willing and able to comply with all scheduled visits, the investigational plan, laboratory tests, lifestyle considerations, and other study procedures
  • Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study
  • Capable of giving signed informed consent as described in the protocol, which includes compliance with the requirements and restrictions listed in the informed consent document (ICD) and in the protocol

Who cannot take part

  • Current heart disease, uncontrolled hypertension, or a prior history of myocarditis or pericarditis
  • Prior history of ischemic stroke or transient ischemic attack
  • Prior history of Guillain-Barré syndrome (GBS)
  • Receipt of chronic medications with known systemic immunosuppressant effects (including cytotoxic agents or systemic corticosteroids), or radiotherapy, within 60 days before enrollment through conclusion of the study
  • Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies used for the treatment or prevention of COVID 19 or those that are considered immunosuppressive, from 90 days before study intervention administration, or planned receipt throughout the study
  • Vaccination with any investigational or licensed influenza vaccine within 6 months (180 days) before study intervention administration, or ongoing receipt of chronic antiviral therapy with activity against influenza
  • Participation in other studies involving administration of an investigational product within 28 days prior to, and/or during, participation in this study
  • Current alcohol abuse or drug addiction that in the opinion of the investigator might interfere with the study conduct or completion
  • Known infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV)
  • History of severe adverse reaction associated with any vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study interventions
  • Participants with a history of autoimmune disease or an active autoimmune disease requiring therapeutic intervention, including but not limited to systemic or cutaneous lupus erythematosus, autoimmune arthritis/rheumatoid arthritis, multiple sclerosis, Sjögren's syndrome, idiopathic thrombocytopenia purpura, glomerulonephritis, autoimmune thyroiditis, temporal arteritis, psoriasis, and/or insulin-dependent diabetes mellitus
  • Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection
  • Vaccination with any investigational or licensed COVID-19 vaccine within 6 months (180 days) before study intervention administration
  • Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study
  • Immunocompromised individuals with known or suspected immunodeficiency, determined by history and/or laboratory/physical examination
  • Women who are pregnant, plan to become pregnant during the study, or are breastfeeding
  • Participants with a calculated BMI of ≥35
  • Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members
  • Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily

Where in United States

  • JEM Research InstituteAtlantis, United States
  • Charlottesville Medical ResearchCharlottesville, United States
  • Centricity Research Columbus Ohio MultispecialtyColumbus, United States
  • Indago Research & Health Center, IncHialeah, United States
  • East-West Medical Research InstituteHonolulu, United States
  • DM Clinical Research - BellaireHouston, United States
  • DM Clinical Research- CyfairHouston, United States
  • Orange County Research CenterLake Forest, United States
  • Las Vegas Clinical TrialsLas Vegas, United States
  • Optimal ResearchMelbourne, United States
  • SMS Clinical ResearchMesquite, United States
  • Clinical Research ConsultingMilford, United States
  • Clinical Research Associates, Inc.Nashville, United States
  • Las Vegas Clinical TrialsNorth Las Vegas, United States
  • Headlands Research OrlandoOrlando, United States
  • Optimal ResearchPeoria, United States
  • ActivMed Practices & Research, LLC.Portsmouth, United States
  • Rochester Clinical Research, LLCRochester, United States
  • Clinical Trials of Texas LLCSan Antonio, United States
  • IMA Clinical Research San AntonioSan Antonio, United States
  • Bio-Kinetic Clinical Applications LLC DBA QPS-MO(Patient Screening Center)Springfield, United States
  • Bio-Kinetic Clinical Applications, LLC dba QPS-MOSpringfield, United States
  • Bio-Kinetic Clinical Applications, LLD dba QPS-MOSpringfield, United States
  • Clinical Research AtlantaStockbridge, United States
  • DM Clinical Research - MDCTomball, United States
  • Orange County Research CenterTustin, United States
  • Diablo Clinical Research, Inc.Walnut Creek, United States
  • GW Medical Faculty AssociatesWashington D.C., United States
  • GW Vaccine Research UnitWashington D.C., United States
  • Clinical Site Partners, LLC dba Flourish ResearchWinter Park, United States

About the trial

What the trial wants to find out

The purpose of this clinical trial is to see if combining a licensed COVID-19 vaccine and a licensed influenza vaccine into a single shot is safe and can help produce antibodies to defend the body against both SARS-CoV-2 (the virus that causes COVID-19) and influenza. Participants enrolled in this trial will be healthy adults, 50 years of age or older.

The 4 groups in the trial

  • BNT162b2 (Omi XBB.1.5)/RIV and placeboTreatment being tested

    Participants will receive a single injection combination of BNT162b2 (Omi XBB.1.5) and RIV and normal saline placebo

    Treatment: BNT162b2 (Omi XBB.1.5)/RIV and Normal saline placebo

  • BNT162b2 (Omi XBB.1.5) and RIVTreatment being tested

    Participants will receive BNT162b2 (Omi XBB.1.5) and RIV

    Treatment: BNT162b2 (Omi XBB.1.5) and RIV

  • BNT162b2 (Omi XBB.1.5) and placeboExisting treatment, for comparison

    Participants will receive BNT162b2 (Omi XBB.1.5) and normal saline placebo

    Treatment: BNT162b2 (Omi XBB.1.5) and Normal saline placebo

  • RIV and placeboExisting treatment, for comparison

    Participants will receive RIV and normal saline placebo

    Treatment: RIV and Normal saline placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1/2 Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA COVID-19 Vaccine and a Recombinant Influenza Vaccine Administered as a Single Injection in Healthy Adults 50 Years of Age or Older
Record updated
30 September 2025